Aldosterone and cardiovascular disease: The heart of the matter

Trends in Endocrinology and Metabolism

Volumn 24, Issue 1, 2013, Pages 21-30

  He, B Julie ^a   Anderson, Mark E ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Aldosterone; CaMKII; Heart failure; Signaling

Indexed keywords

ADAMTS1 PROTEIN; ADIPONECTIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FAD286; GELATINASE B; LCI699; MICRORNA; MINERALOCORTICOID RECEPTOR; PLACEBO; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION REDUCTION REACTION; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDOX STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS;

EID: 84871670499     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.09.004     Document Type: Review

References (100)

1. Lopez A.D., et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
2. Pitt B., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
3. Pitt B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
4. Zannad F., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 364:11-21.
5. Dorn G.W. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat. Rev. Cardiol. 2009, 6:283-291.
6. Qin W., et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. 2003, 93:69-76.
7. Tsybouleva N., et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004, 109:1284-1291.
8. Hayashi H., et al. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. 2008, 31:363-375.
9. He B.J., et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 2011, 17:1610-1618.
10. Kushnir A., et al. Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10274-10279.
11. Wu Y., et al. Calmodulin kinase II is required for fight or flight sinoatrial node physiology. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:5972-5977.
12. Erickson J.R., et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008, 133:462-474.
13. Erickson J.R., et al. CaMKII in the cardiovascular system: sensing redox states. Physiol. Rev. 2011, 91:889-915.
14. Zhang R., et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 2005, 11:409-417.
15. Milliez P., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005, 45:1243-1248.
16. Sam F., et al. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology 2010, 151:322-331.
17. Martos R., et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur. J. Heart Fail. 2009, 11:191-197.
18. Collier P., et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. Eur. J. Heart Fail. 2011, 13:1087-1095.
19. Martos R., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
20. Buralli S., et al. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am. J. Cardiol. 2010, 105:853-856.
21. Brown N.J., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J. Clini. Endocrinol. Metab. 2000, 85:336-344.
22. Thum T., et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur. Heart J. 2011, 32:1275-1286.
23. Peters J., et al. Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1845-H1852.
24. Yoshida Y., et al. Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes. Circ. J. 2010, 74:156-162.
25. Grossmann C., et al. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1790-E1800.
26. Stow L.R., et al. Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1). J. Biol. Chem. 2009, 284:30087-30096.
27. Kiyosue A., et al. Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. Hypertens. Res. 2011, 34:1283-1287.
28. Zhang Q., et al. The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A. Hypertens. Res. 2008, 31:1251-1256.
29. Seiferth A., et al. The phosphatase calcineurin PP2BAbeta mediates part of mineralocorticoid receptor transcriptional activity. FASEB J. 2012, 26:2327-2337.
30. Chu P.Y., et al. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ. Heart Fail. 2011, 4:651-658.
31. Fraccarollo D., et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 2008, 51:905-914.
32. Beygui F., et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am. Heart J. 2010, 160:642-648.
33. + exchanger via transactivation of the epidermal growth factor receptor. Hypertension 2011, 58:912-919.
34. Grossmann C., Gekle M. Interaction between mineralocorticoid receptor and epidermal growth factor receptor signaling. Mol. Cell. Endocrinol. 2012, 350:235-241.
35. Latouche C., et al. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology 2010, 151:4467-4476.
36. Nakamura K., et al. Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction. J. Biochem. 2004, 136:439-446.
37. Sawathiparnich P., et al. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J. Clin. Endocrinol. Metab. 2002, 87:448-452.
38. Han Y.P., et al. Proteolytic activation of matrix metalloproteinase-9 in skin wound healing is inhibited by alpha-1-antichymotrypsin. J. Invest. Dermatol. 2008, 128:2334-2342.
39. Di Zhang A., et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008, 52:1060-1067.
40. Azibani F., et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 2012, 59:1179-1187.
41. Azibani F., et al. Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. PLoS ONE 2012, 7:e38197.
42. Ruhs S., et al. Modulation of transcriptional mineralocorticoid receptor activity by nitrosative stress. Free Radic. Biol. Med. 2012, 53:1088-1100.
43. Latouche C., et al. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 2012, 59:966-972.
44. Ambroisine M.L., et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 2007, 116:2435-2443.
45. Benard L., et al. Effects of aldosterone on coronary function. Pharmacol. Rep. 2009, 61:58-66.
46. Lopez J.E., et al β-Myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ. Res. 2011, 109:629-638.
47. Batenburg W.W., et al. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc. Res. 2012, 94:136-143.
48. Bogdarina I.G., et al. Characterization of the angiotensin (AT1b) receptor promoter and its regulation by glucocorticoids. J. Mol. Endocrinol. 2009, 43:73-80.
49. Yamada M., et al. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc. Res. 2008, 79:169-178.
50. Lemarie C.A., et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ. Res. 2009, 105:852-859.
51. Lemarie C.A., et al. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J. Mol. Med. 2008, 86:673-678.
52. Reil J.C., et al. Aldosterone promotes atrial fibrillation. Eur. Heart J. 2012, 33:2098-2108.
53. Ouvrard-Pascaud A., et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005, 111:3025-3033.
54. Lalevee N., et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc. Res. 2005, 67:216-224.
55. Muto T., et al. Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2710-H2718.
56. 2+ current in adult rat cardiomyocytes. Circ. Res. 1999, 85:1139-1145.
57. Perrier E., et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004, 110:776-783.
58. Gomez A.M., et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009, 119:2179-2187.
59. Lin Z., et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12103-12108.
60. Beygui F., et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006, 114:2604-2610.
61. Palmer B.R., et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur. Heart J. 2008, 29:2489-2496.
62. Funder J.W., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008, 93:3266-3281.
63. Sheppard K.E., Funder J.W. Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus: direct binding studies. J. Steroid Biochem. 1987, 28:737-742.
64. Mihailidou A.S., et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009, 54:1306-1312.
65. Albiston A.L., et al. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 1994, 105:R11-R17.
66. Lombes M., et al. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175-182.
67. Takeda M., et al. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens. Res. 2007, 30:427-437.
68. Klusonova P., et al. Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart. Endocrinology 2009, 150:4270-4277.
69. De-An P., et al. Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation. Clin. Cardiol. 2010, 33:23-29.
70. Tsai C.T., et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J. Am. Coll. Cardiol. 2010, 55:758-770.
71. Chai W., et al. Steroidogenesis vs steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?. J. Hypertens. 2010, 28:1044-1053.
72. Fuller P.J., et al. Mechanisms of ligand specificity of the mineralocorticoid receptor. J. Endocrinol. 2012, 213:15-24.
73. Silvestre J.S., et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 1998, 273:4883-4891.
74. Hayashi M., et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 2001, 38:1375-1382.
75. Usher M.G., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Investig. 2010, 120:3350-3364.
76. Condon J.C., et al. Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 2002, 143:3651-3657.
77. Uruno A., et al. Peroxisome proliferator-activated receptor-γ suppresses CYP11B2 expression and aldosterone production. J. Mol. Endocrinol. 2011, 46:37-49.
78. Lenzini L., et al. Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension 2007, 50:1106-1113.
79. 2+/calmodulin-dependent protein kinase II. J. Clin. Invest. 2006, 116:2403-2412.
80. Pezzi V., et al. Role of calmodulin-dependent protein kinase II in the acute stimulation of aldosterone production. J. Steroid Biochem. Mol. Biol. 1996, 58:417-424.
81. Maeder M.T., Kaye D.M. Heart failure with normal left ventricular ejection fraction. J. Am. Coll. Cardiol. 2009, 53:905-918.
82. Favre J., et al. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H2035-H2043.
83. Deswal A., et al. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J. Card. Fail. 2011, 17:634-642.
84. Zhang Y., et al. Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. Int. J. Cardiol. 2011, 10.1016/j.ijcard.2011.10.089.
85. Desai A.S., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am. Heart J. 2011, 162:966-972.
86. Tsutsui H., et al. Oxidative stress and heart failure. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2181-H2190.
87. Lonn E., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293:1338-1347.
88. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33. Heart Protection Study Collaborative Group.
89. Jauslin M.L., et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003, 17:1972-1974.
90. Chen C.H., et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008, 321:1493-1495.
91. Ohmine T., et al. The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. Hypertens. Res. 2009, 32:690-699.
92. Stas S., et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007, 148:3773-3780.
93. Calhoun D.A., et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011, 124:1945-1955.
94. Amar L., et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010, 56:831-838.
95. Gamliel-Lazarovich A., et al. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J. Hypertens. 2010, 28:1900-1907.
96. Mulder P., et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart J. 2008, 29:2171-2179.
97. Keidar S., Gamliel-Lazarovich A. Letter by Keidar and Gamliel-Lazarovich regarding article, 'effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial'. Circulation 2012, 125:e653.
98. LaSala D., et al. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Anal. Biochem. 2009, 394:56-61.
99. Adams C.M., et al. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11beta-hydroxylase. Bioorg. Med. Chem. Lett. 2010, 20:4324-4327.
100. Roumen L., et al. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J. Med. Chem. 2010, 53:1712-1725.